Combinatorial therapy for triple negative breast cancer using hyperstar polymer-based nanoparticles

Chem Commun (Camb). 2015 Dec 4;51(93):16710-3. doi: 10.1039/c5cc07709e. Epub 2015 Oct 5.

Abstract

We report the ability of a novel combinatorial therapy obtained from nanoparticles of hyperstar polymers encompassing drugs to selectively target triple negative breast cancer (TNBC) cell proliferation through STAT3 and topoisomerase-II pathways. This nano-cocktail was at least two to four fold better than the individual drugs and 6-20 times more selective than the parent drugs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • DNA Topoisomerases, Type II / metabolism
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Humans
  • Nanoparticles / chemistry*
  • Polymers / chemical synthesis
  • Polymers / chemistry
  • Polymers / pharmacology*
  • STAT3 Transcription Factor / antagonists & inhibitors
  • STAT3 Transcription Factor / metabolism
  • Structure-Activity Relationship
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Polymers
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • DNA Topoisomerases, Type II